Rexahn Pharmaceuticals Inc. (RNN)’s Financial Results Comparing With Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)

Rexahn Pharmaceuticals Inc. (NYSEAMERICAN:RNN) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rexahn Pharmaceuticals Inc. N/A 0.00 14.37M -0.47 0.00
Aeglea BioTherapeutics Inc. 3.89M 59.30 44.35M -1.88 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Rexahn Pharmaceuticals Inc. 0.00% -119.8% -71.6%
Aeglea BioTherapeutics Inc. -1,140.10% -62.1% -56%


The Current Ratio and Quick Ratio of Rexahn Pharmaceuticals Inc. are 4.1 and 4.1 respectively. Its competitor Aeglea BioTherapeutics Inc.’s Current Ratio is 9.4 and its Quick Ratio is 9.4. Aeglea BioTherapeutics Inc. can pay off short and long-term obligations better than Rexahn Pharmaceuticals Inc.

Insider and Institutional Ownership

Roughly 9.3% of Rexahn Pharmaceuticals Inc. shares are held by institutional investors while 75.3% of Aeglea BioTherapeutics Inc. are owned by institutional investors. Insiders held roughly 0.2% of Rexahn Pharmaceuticals Inc.’s shares. Comparatively, Aeglea BioTherapeutics Inc. has 1.1% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Rexahn Pharmaceuticals Inc. 3.48% -16.3% -51.51% -67.96% -65.28% -42.13%
Aeglea BioTherapeutics Inc. -0.35% -7% -1.16% -21.22% 23.91% 13.48%

For the past year Rexahn Pharmaceuticals Inc. had bearish trend while Aeglea BioTherapeutics Inc. had bullish trend.


Aeglea BioTherapeutics Inc. beats on 6 of the 9 factors Rexahn Pharmaceuticals Inc.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companyÂ’s clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma. In addition, the company is involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Its human enzymes are designed to degrade specific amino acids in the blood. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies. Its pipeline of engineered human enzyme product candidates in preclinical development includes AEB3103, an enzyme that degrades the amino acids cysteine to target cancer to oxidative stress; AEB2109, an enzyme that degrades the amino acid methionine to target methionine dependent cancers; and AEB4104, an engineered human enzyme to treat another inborn errors of metabolism by degrading the amino acid homocysteine. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea Biotherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.